Next-Generation Sequencing (NGS)-Based Molecular Diagnostics Market Report 2025

The next-generation sequencing (NGS)-based molecular diagnostics market size has grown strongly in recent years. It will grow from $2.1 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period is linked to increasing demand for personalized medicine, wider adoption of next-generation sequencing in clinical settings, growing awareness among clinicians and patients, greater availability of cost-effective NGS platforms, and expanding applications in non-invasive prenatal testing.

The next-generation sequencing (NGS)-based molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.01 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth projected for the forecast period is driven by rising demand for decentralized diagnostic solutions, increasing use of artificial intelligence in NGS data interpretation, growing burden of antibiotic resistance, enhanced regulatory support for NGS-based tests, and greater utilization of NGS in pharmacogenomics. Primary trends during the forecast period include advancements in sequencing accuracy, technology-driven automation in sample preparation, integration with pharmaceutical development pipelines, incorporation of NGS into public health surveillance, and development of disease-specific NGS panels.

The rising incidence of infectious diseases is expected to drive growth in the next-generation sequencing (NGS)-based molecular diagnostics market in the coming years. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that invade and multiply within the body, disrupting normal functions. Increasing global travel and migration contribute to the spread of pathogens across regions and borders, fueling the rise in infectious disease cases. NGS-based molecular diagnostics aids in detecting these diseases by offering comprehensive and precise analysis of pathogens, enabling simultaneous identification of multiple microorganisms, which shortens diagnostic time and improves treatment accuracy and patient care. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7%, rising from 4,380 in 2022 to 4,850 in 2023. Consequently, the growing incidence of infectious diseases is propelling the demand for NGS-based molecular diagnostics.

Key players in the NGS-based molecular diagnostics market are developing advanced products such as targeted NGS panels to improve the accuracy, accessibility, and efficiency of genetic testing. These NGS panels analyze specific genes or genomic regions simultaneously to detect hereditary or somatic mutations quickly and accurately. For instance, in May 2022, Genes2Me Pvt. Ltd., an Indian medical equipment manufacturer, introduced a comprehensive series of NGS panels aimed at oncology, personalized medicine, and hereditary disease diagnostics. These panels cover clinically significant genes with high sensitivity and detect various genomic alterations, including single-nucleotide variants, insertions/deletions, copy number variations, microsatellite instability, fusions, oncogenic viruses, and tumor mutation burden. Their PAN cancer panel targets about 525 genes, requiring only 50 ng of nucleic acid, and supports streamlined workflows compatible with major NGS platforms.

In January 2023, QIAGEN NV, a molecular diagnostics and life sciences company based in Germany, acquired Verogen Inc. for an undisclosed sum. This acquisition aims to enhance QIAGEN’s leadership in human identification and forensic genomics by integrating Verogen’s specialized NGS technologies into its broader molecular diagnostics portfolio. This expansion strengthens QIAGEN’s presence in public sector forensics and private sector applications such as genetic genealogy. Verogen Inc. is a US-based company specializing in NGS solutions for forensic genomics.

Major players in the next-generation sequencing (NGS)-based molecular diagnostics market are Thermo Fisher Scientific, Siemens Healthineers AG, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Amoy Diagnostics Co. Ltd., Tempus Labs Inc., Myriad Genetics Inc., Epigenomics AG, Precision for Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., Caris Life Sciences Inc., Foundation Medicine Inc., Oxford Nanopore Technologies Ltd., Freenome Inc., Burning Rock Biotech, Element Biosciences Inc., Asuragen Inc., Bionano Genomics Inc., Genomic Health Inc., and TATAA Biocenter AB.

North America was the largest region in the next-generation sequencing (NGS)-based molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation sequencing (NGS)-based molecular diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the next-generation sequencing (NGS)-based molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Next-generation sequencing (NGS)-based molecular diagnostics is a technology-driven approach that uses high-throughput sequencing to analyze genetic material with precision and speed. It enables detection of genetic variations, mutations, and disease markers at the molecular level, providing detailed insights into the genetic basis of health and disease. This approach supports precise, data-driven diagnostics by combining sequencing technologies with advanced bioinformatics.

The primary types of NGS-based molecular diagnostics include instruments, reagents and consumables, software and services, panels and assays, and sample preparation kits. NGS instruments are the hardware platforms, such as sequencers and automation workstations, used to perform high-throughput DNA/RNA sequencing. Applications include microbiology, infectious diseases, oncology, genetic testing, and other areas. End users include research centers, academic institutions, hospitals, clinical laboratories, and other organizations.

The next-generation sequencing (NGS) based molecular diagnostics market research report is one of a series of new reports that provides next-generation sequencing (NGS) based molecular diagnostics market statistics, including next-generation sequencing (NGS) based molecular diagnostics industry global market size, regional shares, competitors with a next-generation sequencing (NGS) based molecular diagnostics market share, detailed next-generation sequencing (NGS) based molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (NGS) based molecular diagnostics industry. The next-generation sequencing (NGS)-based molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation sequencing (NGS)-based molecular diagnostics market includes revenues earned by entities by providing services, such as clinical genomic testing, cancer genomic profiling, infectious disease detection, liquid biopsy testing, and pharmacogenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS)-based molecular diagnostics market also includes sales of tumor mutation panels, carrier screening kits, drug response panels, companion diagnostic kits, and whole-genome metagenomics kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.